Potential novel anxiolytic drugs

Current Pharmaceutical Design

Volumn 14, Issue 33, 2008, Pages 3534-3546

  Christmas, David ^a   Hood, S ^b   Nutt, D ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; AGOMELATINE; ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; CLONIDINE; CYCLOSERINE; DERAMICLINE; FENOBAM; IFENPRODIL; OCINAPLON; PAGOCLONE; PAROXETINE; PLACEBO; SAREDUTANT; SEROTONIN UPTAKE INHIBITOR; TALAGLUMETAD; TIAGABINE; UNCLASSIFIED DRUG; VOFOPITANT; ZOLPIDEM;

AMNESIA; ANXIETY DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; FOCAL EPILEPSY; GABAERGIC SYSTEM; GENERALIZED ANXIETY DISORDER; HUMAN; LIVER TOXICITY; MAJOR DEPRESSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PRIORITY JOURNAL; RAPHE NUCLEUS; RECEPTOR DOWN REGULATION; RECURRENCE RISK; REVIEW; SEDATION; SEROTONINERGIC SYSTEM; SIDE EFFECT; SOCIAL PHOBIA;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; HUMANS;

EID: 59849098042     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786848775     Document Type: Review

References (172)

1. Klein DF. Delineation of two drug responsive anxiety syndromes. Psychopharmacology 1964; 5(6): 39-408.
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51(1): 8-19.
3. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008; 25(1): 72-90.
4. Argyropoulos SV, Hood SD, Adrover M, Bell CJ, Rich AS, Nash JR, et al. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol Psychiatry 2004; 56(7): 503-9.
5. McNaughton N, Corr PJ. A two-dimensional neuropsychology of defense: fear/anxiety and defensive distance. Neurosci Biobehav Rev 2004; 28(3): 285-305.
6. McNaughton N, Gray JA. Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. J Affect Disord 2000; 61(3): 161-76.
7. Gray JA. The psychophysiological basis of introversion-extraversion. Behav Res Ther 1970; 8(3): 249-66.
8. Blanchard RJ, Blanchard DC. Attack and defense in rodents as ethoexperimental models for the study of emotion. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13(Suppl): S3-14.
9. Shuhama R, Del-Ben CM, Loureiro SR, Graeff FG. Animal defense strategies and anxiety disorders. An Acad Bras Cienc 2007; 79(1): 97-109.
10. Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 2001; 179: 390-6.
11. Kalueff A, Nutt DJ. Role of GABA in memory and anxiety. Depress Anxiety 1996; 4(3): 100-10.
12. Nutt DJ, Glue P, Lawson C, Wilson S. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry 1990; 47(10): 917-25.
13. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: Preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998; 55(8): 715-20.
14. Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spect 2005; 10: 49-56.
15. Whiting PJ. GABA-A receptors: A viable target for novel anxiolytics? Curr Opin Pharmacol 2006; 6(1): 24-9.
16. Rudolph U, Mohler H. GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr Opin Pharmacol 2006; 6(1): 18-23.
17. Atack JR, Hutson PH, Collinson N, Marshall G, Bentley G, Moyes C, et al. Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors. Br J Pharmacol 2005; 144(3): 357-66.
18. Nutt DJ, Besson M, Wilson SJ, Dawson GR, Lingford-Hughes AR. Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology 2007; 53(7): 810-20.
19. Olsen RW, Chang CS, Li G, Hanchar HJ, Wallner M. Fishing for allosteric sites on GABA(A) receptors. Biochem Pharmacol 2004; 68(8): 1675-84.
20. Dias R, Sheppard WF, Fradley RL, Garrett EM, Stanley JL, Tye SJ, et al. Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci 2005; 25(46): 10682-8.
21. Polsky-Fisher SL, Vickers S, Cui D, Subramanian R, Arison BH, Agrawal NG, et al. Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers. Drug Metab Dispos 2006; 34(6): 1004-11.
22. Atack JR, Wafford KA, Tye SJ, Cook SM, Sohal B, Pike A, et al. TPA023 [7-(1, 1-dimethylethyl)-6-(2-ethyl-2H-1, 2, 4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1, 2, 4-triazolo[4, 3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 2006; 316(1): 410-22.
23. McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 2000; 3(6): 587-92.
24. Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Decobert M, et al. SL651498: An anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors. J Pharmacol Exp Ther 2001; 298(2): 753-68.
25. de Haas SL, de Visser SJ, van der Post JP, Schoemaker RC, van DK, Murphy MG, et al. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2, 3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. J Psychopharmacol 2008; 22(1): 24-32.
26. Lingford-Hughes A, Wilson SJ, Feeney A, Grasby PG, Nutt DJ. A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist. Psychopharmacology (Berl) 2005; 180(4): 789-91.
27. Sandford JJ, Forshall S, Bell C, Argyropoulos S, Rich A, D'Orlando KJ, et al. Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J Psychopharmacol 2001; 15(3): 205-8.
28. Lippa A, Czobor P, Stark J, Beer B, Kostakis E, Gravielle M, et al. Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. Proc Natl Acad Sci USA 2005; 102(20): 7380-5.
29. Bailey J, Papadopoulos A, Seddon K, Nutt D. A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO2 models of experimental human anxiety. J Psychopharmacol 2008; In press
30. Zwanzger P, Eser D, Padberg F, Baghai TC, Schule C, Rotzer F, et al. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress Anxiety 2003; 18(3): 140-3.
31. Dunlop BW, Papp L, Garlow SJ, Weiss PS, Knight BT, Ninan PT. Tiagabine for social anxiety disorder. Hum Psychopharmacol 2007; 22(4): 241-4.
32. Pollack MH, Roy-Byrne PP, Van AM, Snyder H, Brown C, Ondrasik J, et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: Results of a placebo-controlled study. J Clin Psychiatry 2005; 66(11): 1401-8.
33. Olivier B, Soudijn W, van Wijngaarden I. The 5-HT1A receptor and its ligands: Structure and function. Prog Drug Res 1999; 52: 103-65.
34. McGuirk J, Muscat R, Willner P. Effects of chronically administered fluoxetine and fenfluramine on food intake, body weight and the behavioural satiety sequence. Psychopharmacology (Berl) 1992; 106(3): 401-7.
35. McGuirk J, Muscat R, Willner P. Effects of the 5-HT uptake inhibitors, femoxetine and paroxetine, and a 5-HT1A/B agonist, eltoprazine, on the behavioural satiety sequence. Pharmacol Biochem Behav 1992; 41(4): 801-5.
36. Monti JM, Monti D. Role of dorsal raphe nucleus serotonin 5-HT1A receptor in the regulation of REM sleep. Life Sci 2000; 66(21): 1999-2012.
37. Bagdy G, Makara GB. Hypothalamic paraventricular nucleus lesions differentially affect serotonin-1A (5-HT1A) and 5-HT2 receptor agonist-induced oxytocin, prolactin, and corticosterone responses. Endocrinology 1994; 134(3): 1127-31.
38. Baldwin D, Anderson I, Nutt D, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psyhcopharmacology. J Psychpharmacol 2005; 19(6): 567-96.
39. Schruers K, Griez E. The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder. J Psychopharmacol 2004; 18(4): 553-8.
40. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 1997; 22(5): 332-40.
41. Bell C, Forshall S, Adrover M, Nash J, Hood S, Argyropoulos S, et al. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol 2002; 16(1): 5-14.
42. Perna G, Bertani A, Caldirola D, Di PD, Migliarese G, Bellodi L. Modulation of hyperreactivity to 35% CO2 after one week of treatment with paroxetine and reboxetine: A double-blind, randomized study. J Clin Psychopharmacol 2004; 24(3): 277-82.
43. Hood SD, Bell CJ, Nutt DJ. Acute tryptophan depletion. Part I: Rationale and methodology. Aust N Z J Psychiatry 2005; 39(7): 558-64.
44. Schruers K, van Diest R, Nicolson N, Griez E. L-5-hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers. Psychopharmacology (Berl) 2002; 161(4): 365-9.
45. Charney DS, Woods SW, Goodman WK, Heninger GR. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987; 92(1): 14-24.
46. Tancer ME, Mailman RB, Stein MB, Mason GA, Carson SW, Golden RN. Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia. Anxiety 1994; 1(5): 216-23.
47. Targum SD. Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biol Psychiatry 1990; 28(1): 21-34.
48. Bell CJ, Nutt DJ. Serotonin and panic. Br J Psychiatry 1998; 172: 465-71.
49. Sinclair L, Christmas D, Hood S, Potokar J, Robertson A, Isaac A, et al. A systematic review of antidepressant induced jitteriness/anxiety syndrome. Br J Psychiatry 2008; In press.
50. Esler M, Lambert E, Alvarenga M, Socratous F, Richards J, Barton D, et al. Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: Reduction by a selective serotonin reuptake inhibitor. Stress 2007; 10(3): 295-304.
51. Blier P, de Montignyc C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: Preclinical evidence. J Clin Psychiatry 1990; 51(Suppl): 14-20; discussion 21: 14-20.
52. Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 2001; 4(4): 399-408.
53. Tork I. Anatomy of the serotonergic system. Ann N Y Acad Sci 1990; 600: 9-34.
54. Azmitia EC, Whitaker PM. Anatomy, cell biology and plasticity of the serotonergic system. Neuropsychopharmacological implications for the actions of psychotropic drugs. In: Bloom FE, Kupfer DJ, Eds. Psychopharmacology: The Fourth Generation of Progress, Raven Press, New York 1995; 443-490.
55. Deakin JF. Depression and 5HT. Int Clin Psychopharmacol 1991; 6(Suppl 3): 23-8.
56. Johnson PL, Lightman SL, Lowry CA. A functional subset of serotonergic neurons in the rat ventrolateral periaqueductal gray implicated in the inhibition of sympathoexcitation and panic. Ann N Y Acad Sci 2004; 1018: 58-64.
57. Den Boer JA, Westenberg HG. Serotonin function in panic disorder: A double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 1990; 102(1): 85-94.
58. Kahn RS, Wetzler S, Asnis GM, Kling MA, Suckow RF, van Praag HM. Effects of m-chlorophenylpiperazine in normal subjects: A dose-response study. Psychopharmacology (Berl) 1990; 100(3): 339-44.
59. Targum SD. Cortisol response during different anxiogenic challenges in panic disorder patients. Psychoneuroendocrinology 1992; 17(5): 453-8.
60. Anderson IM, Mortimore C. 5-HT and human anxiety. Evidence from studies using acute tryptophan depletion. Adv Exp Med Biol 1999; 467: 43-55.
61. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci USA 1998; 95(18): 10734-9.
62. Tauscher J, Bagby RM, Javanmard M, Christensen BK, Kasper S, Kapur S. Inverse relationship between serotonin 5-HT(1A) receptor binding and anxiety: A [(11)C]WAY-100635 PET investigation in healthy volunteers. Am J Psychiatry 2001; 158(8): 1326-8.
63. Nash J, Sargent P, Rabiner E, Hood S, Argyropoulos S, Potokar J, et al. A positron emission tomography study of serotonin 5-HT1A receptor availability in untreated and recovered patients with panic disorder. Br J Psychiatry 2008; 193: 1-6.
64. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 2004; 24(3): 589-91.
65. Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, et al. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry 2007; 61(9): 1081-9.
66. van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of buspirone in social phobia: A double-blind placebo-controlled study. J Clin Psychiatry 1997; 58(4): 164-8.
67. Sheehan DV, Raj AB, Sheehan KH, Soto S. Is buspirone effective for panic disorder? J Clin Psychopharmacol 1990; 10(1): 3-11.
68. van Vliet IM, Westenberg HG, den Boer JA. Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology (Berl) 1996; 127(2): 174-80.
69. Choy Y, Peselow ED, Case BG, Pressman MA, Luff JA, Laje G, et al. Three-year medication prophylaxis in panic disorder: To continue or discontinue? A naturalistic study. Compr Psychiatry 2007; 48(5): 419-25.
70. Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: Focus on novel therapeutic strategies. Therapie 2005; 60(5): 441-60.
71. Griebel G, Perrault G, Sanger DJ. A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology 1997; 36(6): 793-802.
72. Eser D, Baghai TC, Moller HJ. Evidence of agomelatine's antidepressant efficacy: The key points. Int Clin Psychopharmacol 2007; 22(Suppl 2): S15-9.
73. Gruca P, Przegalinski E, Mrowiec S, Lason M, Papp M. Evidence for antidepressant and anxiolytic-like activities of melatonin and agomelatine in animal models. Eur Neuropsychopharmacol 2004; 14(Suppl 3): S230.
74. Weisstaub NV, Zhou M, Lira A, Lambe E, Gonzalez-Maeso J, Hornung JP, et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 2006; 313(5786): 536-40.
75. Deakin JF. 5HT2 receptors, depression and anxiety. Pharmacol Biochem Behav 1988; 29(4): 819-20.
76. Nogueira RL, Graeff FG. Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion. Pharmacol Biochem Behav 1995; 52(1): 1-6.
77. Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, et al. Deramciclane in the treatment of generalized anxiety disorder: A placebo-controlled, double-blind, dose-finding study. Eur Neuropsychopharmacol 2005; 15(6): 617-23.
78. Delgado M, Caicoya AG, Greciano V, Benhamu B, Lopez-Rodriguez ML, Fernandez-Alfonso MS, et al. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors. Eur J Pharmacol 2005; 511(1): 9-19.
79. KLEIN DF, FINK M. Psychiatric reaction patterns to imipramine. Am J Psychiatry 1962; 119: 432-8.
80. Mavissakalian M, Perel JM, Michelson L. The relationship of plasma imipramine and N-desmethylimipramine to improvement in agoraphobia. J Clin Psychopharmacol 1984; 4(1): 36-40.
81. Nutt DJ, Glue P. Imipramine in panic disorder (1): Clinical response and pharmacological changes. J Psychopharmacol 1991; 5: 56-64.
82. Nutt DJ, Glue P. Imipramine in panic disorder (2): Efects on alpha2-adrenoceptor function. J Psychopharmacol 1991; 5: 135-41.
83. Szabo ST, Blier P. Response of the norepinephrine system to antidepressant drugs. CNS Spectr 2001; 6(8): 679-84.
84. Schank JR, Liles LC, Weinshenker D. Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety. Biol Psychiatry 2008; 63(11): 1007-12.
85. Hein L, Altman JD, Kobilka BK. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999; 402(6758): 181-4.
86. Trendelenburg AU, Trendelenburg M, Starke K, Limberger N. Release-inhibiting alpha 2-adrenoceptors at serotonergic axons in rat and rabbit brain cortex: Evidence for pharmacological identity with alpha 2-autoreceptors. Naunyn Schmiedebergs Arch Pharmacol 1994; 349(1): 25-33.
87. Trendelenburg AU, Starke K, Limberger N. Presynaptic alpha 2A-adrenoceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices. Naunyn Schmiedebergs Arch Pharmacol 1994; 350(5): 473-81.
88. Schramm NL, McDonald MP, Limbird LE. The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J Neurosci 2001; 21(13): 4875-82.
89. Maes M, Van Gastel A, Delmeire L, Kenis G, Bosmans E, Song C. Platelet alpha2-adrenoceptor density in humans: Relationships to stress-induced anxiety, psychasthenic constitution, gender and stress-induced changes in the inflammatory response system. Psychol Med 2002; 32(5): 919-28.
90. Redmond DE, Jr., Huang YH. The primate locus coeruleus and effects of clonidine on opiate withdrawal. J Clin Psychiatry 1982; 43(6 Pt 2): 25-9.
91. Uhde TW, Stein MB, Vittone BJ, Siever LJ, Boulenger JP, Klein E, et al. Behavioral and physiologic effects of short-term and longterm administration of clonidine in panic disorder. Arch Gen Psychiatry 1989; 46(2): 170-7.
92. Charney DS, Heninger GR. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1986; 43(11): 1042-54.
93. Nutt DJ. Increased central alpha 2-adrenoceptor sensitivity in panic disorder. Psychopharmacology (Berl) 1986; 90(2): 268-9.
94. Goldberg MR, Hollister AS, Robertson D. Influence of yohimbine on blood pressure, autonomic reflexes, and plasma catecholamines in humans. Hypertension 1983; 5(5): 772-8.
95. Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1984; 41(8): 751-63.
96. den Boer JA, Westenberg HG. Critical notes on the locus coeruleus hypothesis of panic disorder. Acta Neuropsychiatrica 1993; 5: 48-54.
97. Coupland NJ, Bailey JE, Wilson SJ, Potter WZ, Nutt DJ. A pharmacodynamic study of the alpha 2-adrenergic receptor antagonist ethoxyidazoxan in healthy volunteers. Clin Pharmacol Ther 1994; 56(4): 420-9.
98. Berrios GE, Campbell C, Politynska BE. Autonomic failure, depression and anxiety in Parkinson's disease. Br J Psychiatry 1995; 166(6): 789-92.
99. Tiihonen J, Kuikka J, Bergstrom K, Lepola U, Koponen H, Leinonen E. Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 1997; 154(2): 239-42.
100. Robinson HM, Hood SD, Bell CJ, Nutt DJ. Dopamine and social anxiety disorder. Rev Bras Psiquiatr 2006; 28(4): 263-4.
101. Schneier FR, Liebowitz MR, bi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M. Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry 2000; 157(3): 457-9.
102. Schneier FR, Martinez D, bi-Dargham A, Zea-Ponce Y, Simpson HB, Liebowitz MR, et al. Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: Preliminary findings. Depress Anxiety 2008; 25(1): 1-7.
103. Williams K, Argyropoulos S, Nutt DJ. Amphetamine misuse and social phobia. Am J Psychiatry 2000; 157(5): 834-5.
104. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003; 60(7): 1130-5.
105. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992; 49(4): 290-300.
106. Hood S, Potokar J, Davies S, Hince D, Morris K, Seddon K, et al. Dopaminergic challenges in social anxiety disorder: Evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants. J Psychopharmacol 2009; In press.
107. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007; 113(2): 296-320.
108. Bergink V, van Megen HJ, Westenberg HG. Glutamate and anxiety. Eur Neuropsychopharmacol 2004; 14(3): 175-83.
109. Shigemoto R, Kinoshita A, Wada E, Nomura S, Ohishi H, Takada M, et al. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci 1997; 17(19): 7503-22.
110. Ohishi H, Shigemoto R, Nakanishi S, Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: An in situ hybridization study. J Comp Neurol 1993; 335(2): 252-66.
111. van den Heuvel OA, Veltman DJ, Groenewegen HJ, Witter MP, Merkelbach J, Cath DC, et al. Disorder-specific neuroanatomical correlates of attentional bias in obsessive-compulsive disorder, panic disorder, and hypochondriasis. Arch Gen Psychiatry 2005; 62(8): 922-33.
112. Rauch SL, Shin LM, Wright CI. Neuroimaging studies of amygdala function in anxiety disorders. Ann N Y Acad Sci 2003; 985: 389-410.
113. Rauch SL, Whalen PJ, Shin LM, McInerney SC, Macklin ML, Lasko NB, et al. Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: A functional MRI study. Biol Psychiatry 2000; 47(9): 769-76.
114. Kim M, McGaugh JL. Effects of intra-amygdala injections of NMDA receptor antagonists on acquisition and retention of inhibitory avoidance. Brain Res 1992; 585(1-2): 35-48.
115. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000; 39(9): 1096-103.
116. Plaznik A, Palejko W, Nazar M, Jessa M. Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol 1994; 4(4): 503-12.
117. Kotlinska J, Liljequist S. A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701, 324. Psychopharmacology (Berl) 1998; 135(2): 175-81.
118. Anthony EW, Nevins ME. Anxiolytic-like effects of N-methyl-D-aspartate-associated glycine receptor ligands in the rat potentiated startle test. Eur J Pharmacol 1993; 250(2): 317-24.
119. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008; 63(6): 544-9.
120. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005; 4(2): 131-44.
121. Fraser CM, Cooke MJ, Fisher A, Thompson ID, Stone TW. Interactions between ifenprodil and dizocilpine on mouse behaviour in models of anxiety and working memory. Eur Neuropsychopharmacol 1996; 6(4): 311-6.
122. Kotlinska J, Liljequist S. The putative AMPA receptor antagonist, LY326325, produces anxiolytic-like effects without altering locomotor activity in rats. Pharmacol Biochem Behav 1998; 60(1): 119-24.
123. Alt A, Weiss B, Ornstein PL, Gleason SD, Bleakman D, Stratford RE Jr, et al. Anxiolytic-like effects through a GLUK5 kainate receptor mechanism. Neuropharmacology 2007; 52(7): 1482-7.
124. Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, et al. In vitro and in vivo studies in rats with LY293558 suggest AMPA/ kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. Psychopharmacology (Berl) 2006; 185(2): 240-7.
125. Varty GB, Grilli M, Forlani A, Fredduzzi S, Grzelak ME, Guthrie DH, et al. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: A comparison of efficacy and side-effect profiles. Psychopharmacology (Berl) 2005; 179(1): 207-17.
126. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R. Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: Behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 2003; 14(4): 257-77.
127. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R. Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: Behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 2003; 14(4): 257-77.
128. Page ME, Szeliga P, Gasparini F, Cryan JF. Blockade of the mGlu5 receptor decreases basal and stress-induced cortical norepinephrine in rodents. Psychopharmacology (Berl) 2005; 179(1): 240-6.
129. Patel JB, Martin C, Malick JB. Differential antagonism of the anti-conflict effects of typical and atypical anxiolytics. Eur J Pharmacol 1982; 86(2): 295-8.
130. Friedmann CT, Davis LJ, Ciccone PE, Rubin RT. Phase II double blind controlled study of a new anxiolytic, fenobam (McN-3377). Curr Ther Res 1980; 27: 144-51.
131. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, Allan T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 1982; 2(2): 129-33.
132. Porter RH, Jaeschke G, Spooren W, Ballard TM, Buttelmann B, Kolczewski S, et al. Fenobam: A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 2005; 315(2): 711-21.
133. Ametamey SM, Kessler LJ, Honer M, Wyss MT, Buck A, Hintermann S, et al. Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med 2006; 47(4): 698-705.
134. Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003; 6(3): 189-97.
135. Grillon C, Cordova J, Levine LR, Morgan CA, III. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 2003; 168(4): 446-54.
136. Bergink V, Westenberg HG. Metabotropic glutamate II receptor agonists in panic disorder: A double blind clinical trial with LY354740. Int Clin Psychopharmacol 2005; 20(6): 291-3.
137. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008; 33(7): 1603-10.
138. Tatarczynska E, Klodzinska A, Kroczka B, Chojnacka-Wojcik E, Pilc A. The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology (Berl) 2001; 158(1): 94-9.
139. Johnson MP, Kelly G, Chamberlain M. Changes in rat serum corticosterone after treatment with metabotropic glutamate receptor agonists or antagonists. J Neuroendocrinol 2001; 13(8): 670-7.
140. Fendt M, Schmid S, Thakker DR, Jacobson LH, Yamamoto R, Mitsukawa K, et al. mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity. Mol Psychiatry 2007; 13(10): 970-9.
141. Ebner K, Rupniak NM, Saria A, Singewald N. Substance P in the medial amygdala: Emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA 2004; 101(12): 4280-5.
142. Michelgard A, Appel L, Pissiota A, Frans O, Langstrom B, Bergstrom M, et al. Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry 2007; 61(8): 1002-6.
143. Aguiar MS, Brandao ML. Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test. Physiol Behav 1996; 60(4): 1183-6.
144. Gavioli EC, Canteras NS, De Lima TC. Anxiogenic-like effect induced by substance P injected into the lateral septal nucleus. Neuroreport 1999; 10(16): 3399-403.
145. Shirayama Y, Mitsushio H, Takashima M, Ichikawa H, Takahashi K. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 1996; 739(1-2): 70-8.
146. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006; 31(3): 251-72.
147. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004; 29(2): 385-92.
148. Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 2005; 58(2): 132-42.
149. Eckart K, Jahn O, Radulovic J, Radulovic M, Blank T, Stiedl O, et al. Pharmacology and biology of corticotropin-releasing factor (CRF) receptors. Receptors Channels 2002; 8(3-4): 163-77.
150. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998; 20(6): 1093-102.
151. Arborelius L, Skelton KH, Thrivikraman KV, Plotsky PM, Schulz DW, Owens MJ. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154, 526: Behavioral, endocrine and neurochemical effects in the rat. J Pharmacol Exp Ther 2000; 294(2): 588-97.
152. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 2000; 97(11): 6079-84.
153. Millan MJ, Brocco M, Gobert A, Dorey G, Casara P, Dekeyne A. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154, 526 and DMP695: A comparison to other classes of anxiolytic agent. Neuropsychopharmacology 2001; 25(4): 585-600.
154. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated. J Psychiatr Res 2000; 34(3): 171-81.
155. Ising M, Zimmermann US, Kunzel HE, Uhr M, Foster AC, Learned-Coughlin SM, et al. High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 2007; 32(9): 1941-9.
156. Bailey J, Papadopoulos A, Diaper A, Phillips S, Schmidt M, van der Ark P, et al. Preliminary evidence of efficacy of a CRF1 receptor antagonist in the 7.5% CO2 model of anxiety. 2008.
157. King PJ, Widdowson PS, Doods HN, Williams G. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J Neurochem 1999; 73(2): 641-6.
158. Heilig M. THe NPY system in stress, anxiety and depression. Neuropeptides 38, 214-221. 2004.
159. Primeaux SD, Wilson SP, Cusick MC, York DA, Wilson MA. Effects of altered amygdalar neuropeptide y expression on anxiety-related behaviors. Neuropsychopharmacology 2005; 30(9): 1589-97.
160. Kask A, Rago L, Harro J. Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: Antagonism with diazepam. Eur J Pharmacol 1996; 317(2-3): R3-R4.
161. Kask A, Kivastik T, Rago L, Harro J. Neuropeptide Y Y1 receptor antagonist BIBP3226 produces conditioned place aversion in rats. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23(4): 705-11.
162. Sajdyk TJ, Vandergriff MG, Gehlert DR. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol 1999; 368(2-3): 143-7.
163. Sorensen G, Lindberg C, Wortwein G, Bolwig TG, Woldbye DP. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J Neurosci Res 2004; 77(5): 723-9.
164. Redrobe JP, Dumont Y, Quirion R. Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci 2002; 71(25): 2921-37.
165. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 1991; 48(7): 603-10.
166. Swain J, Koszycki D, Shlik J, Bradwejn J. Pharmacological Challenge Agents in Anxiety. In: Nutt DJ, Ballenger JC Eds. Anxiety Disorders: Blackwell Science 2003; 269-95.
167. Bradwejn J, Koszycki D. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry 1994; 151(2): 261-3.
168. Bradwejn J, Koszycki D, Couetoux du TA, van Megen H, den BJ, Westenberg H. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365, 260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 1994; 51(6): 486-93.
169. Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Chenault A, et al. A placebo-controlled trial of L-365, 260, a CCKB antagonist, in panic disorder. Biol Psychiatry 1995; 37(7): 462-6.
170. Chen Z, Yang J, Tobak A. Designing new treatments for depression and anxiety. IDrugs 2008; 11(3): 189-97.
171. Cunha RA, Ferre S, Vaugeois JM, Chen JF. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des 2008; 14(15): 1512-24.
172. Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, Varella EA, Nicolaides DN. Recent developments in the chemistry and in the biological applications of amidoximes. Curr Pharm Des 2008; 14(10): 1001-47.